KR102084927B1 - 사람화된 ｉｌ-6 및 ｉｌ-6 수용체 - Google Patents
사람화된 ｉｌ-6 및 ｉｌ-6 수용체 Download PDFInfo
- Publication number
- KR102084927B1 KR102084927B1 KR1020147014316A KR20147014316A KR102084927B1 KR 102084927 B1 KR102084927 B1 KR 102084927B1 KR 1020147014316 A KR1020147014316 A KR 1020147014316A KR 20147014316 A KR20147014316 A KR 20147014316A KR 102084927 B1 KR102084927 B1 KR 102084927B1
- Authority
- KR
- South Korea
- Prior art keywords
- mouse
- human
- gene
- protein
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010038501 Interleukin-6 Receptors Proteins 0.000 title abstract description 49
- 102000010781 Interleukin-6 Receptors Human genes 0.000 title description 42
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 180
- 241000699670 Mus sp. Species 0.000 claims abstract description 179
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract description 119
- 102000052611 human IL6 Human genes 0.000 claims abstract description 113
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 claims abstract description 43
- 230000001105 regulatory effect Effects 0.000 claims abstract description 27
- 101100286713 Homo sapiens IL6 gene Proteins 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 129
- 108090000623 proteins and genes Proteins 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 65
- 101000599053 Mus musculus Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 34
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 27
- 210000001185 bone marrow Anatomy 0.000 claims description 24
- 210000000952 spleen Anatomy 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108700024394 Exon Proteins 0.000 claims description 15
- 206010035485 plasmacytosis Diseases 0.000 claims description 15
- 210000003593 megakaryocyte Anatomy 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 13
- 102000018358 immunoglobulin Human genes 0.000 claims description 13
- 230000001086 cytosolic effect Effects 0.000 claims description 12
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 10
- 210000001165 lymph node Anatomy 0.000 claims description 10
- 238000011577 humanized mouse model Methods 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 206010041660 Splenomegaly Diseases 0.000 claims description 6
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 5
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 5
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 5
- 201000006370 kidney failure Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 114
- 229940100601 interleukin-6 Drugs 0.000 description 103
- 210000003719 b-lymphocyte Anatomy 0.000 description 49
- 108020004414 DNA Proteins 0.000 description 34
- 241001529936 Murinae Species 0.000 description 25
- 241000699660 Mus musculus Species 0.000 description 25
- 238000011830 transgenic mouse model Methods 0.000 description 25
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 21
- 206010048998 Acute phase reaction Diseases 0.000 description 20
- 230000004658 acute-phase response Effects 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 239000000523 sample Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 101100286719 Mus musculus Il6 gene Proteins 0.000 description 14
- 238000003753 real-time PCR Methods 0.000 description 14
- 230000009261 transgenic effect Effects 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 101150047862 hil-6 gene Proteins 0.000 description 11
- 108700028369 Alleles Proteins 0.000 description 10
- 101150101999 IL6 gene Proteins 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 230000007170 pathology Effects 0.000 description 10
- 210000004180 plasmocyte Anatomy 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 9
- 102100022338 Integrin alpha-M Human genes 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000007342 reactive astrogliosis Effects 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 206010020880 Hypertrophy Diseases 0.000 description 7
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 108010042685 trinitrophenyl keyhole limpet hemocyanin Proteins 0.000 description 7
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 6
- 102100038081 Signal transducer CD24 Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 230000003393 splenic effect Effects 0.000 description 6
- 210000004885 white matter Anatomy 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 5
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 5
- 102000004225 Cathepsin B Human genes 0.000 description 5
- 108090000712 Cathepsin B Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 102100027584 Protein c-Fos Human genes 0.000 description 5
- 230000011712 cell development Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000006734 Beta-Globulins Human genes 0.000 description 4
- 108010087504 Beta-Globulins Proteins 0.000 description 4
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 4
- 102100039564 Leukosialin Human genes 0.000 description 4
- 206010028289 Muscle atrophy Diseases 0.000 description 4
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003519 mature b lymphocyte Anatomy 0.000 description 4
- 210000000274 microglia Anatomy 0.000 description 4
- 201000000585 muscular atrophy Diseases 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 101100452395 Mus musculus Il6ra gene Proteins 0.000 description 3
- 241000124429 Phlox Species 0.000 description 3
- 208000007452 Plasmacytoma Diseases 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 108700028909 Serum Amyloid A Proteins 0.000 description 3
- 102000054727 Serum Amyloid A Human genes 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000003297 immature b lymphocyte Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000007171 neuropathology Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 3
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 102000005572 Cathepsin A Human genes 0.000 description 2
- 108010059081 Cathepsin A Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 101100452394 Homo sapiens IL6R gene Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000011714 129 mouse Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 1
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914680 Homo sapiens Fanconi anemia group C protein Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108020004509 Intracisternal A-Particle Genes Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 1
- 206010073599 Myeloma cast nephropathy Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010051081 Nodular regenerative hyperplasia Diseases 0.000 description 1
- 101150012195 PREB gene Proteins 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- 101710149067 Paired box protein Pax-5 Proteins 0.000 description 1
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 1
- 108091027569 Z-DNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001056 activated astrocyte Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000004667 early pro-b cell Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116886 human interleukin-6 Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002202 late pro-b cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009681 mesenchymal cell proliferation Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000345 small pre-b cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552900P | 2011-10-28 | 2011-10-28 | |
| US61/552,900 | 2011-10-28 | ||
| US201161556579P | 2011-11-07 | 2011-11-07 | |
| US61/556,579 | 2011-11-07 | ||
| PCT/US2012/062379 WO2013063556A1 (en) | 2011-10-28 | 2012-10-29 | Humanized il-6 and il-6 receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207005686A Division KR102234632B1 (ko) | 2011-10-28 | 2012-10-29 | 사람화된 ｉｌ-6 및 ｉｌ-6 수용체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140091024A KR20140091024A (ko) | 2014-07-18 |
| KR102084927B1 true KR102084927B1 (ko) | 2020-03-06 |
Family
ID=47295138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147014316A Active KR102084927B1 (ko) | 2011-10-28 | 2012-10-29 | 사람화된 ｉｌ-6 및 ｉｌ-6 수용체 |
| KR1020207005686A Active KR102234632B1 (ko) | 2011-10-28 | 2012-10-29 | 사람화된 ｉｌ-6 및 ｉｌ-6 수용체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207005686A Active KR102234632B1 (ko) | 2011-10-28 | 2012-10-29 | 사람화된 ｉｌ-6 및 ｉｌ-6 수용체 |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US8878001B2 (enExample) |
| EP (2) | EP2663575B1 (enExample) |
| JP (2) | JP6120451B2 (enExample) |
| KR (2) | KR102084927B1 (enExample) |
| CN (2) | CN108866101A (enExample) |
| AU (1) | AU2015207889B2 (enExample) |
| BR (1) | BR112014008529A2 (enExample) |
| CA (1) | CA2853731C (enExample) |
| CY (2) | CY1116614T1 (enExample) |
| DK (2) | DK2663575T3 (enExample) |
| ES (2) | ES2525368T3 (enExample) |
| HR (2) | HRP20141192T1 (enExample) |
| HU (1) | HUE033400T2 (enExample) |
| IL (4) | IL231896B (enExample) |
| IN (1) | IN2014CN03920A (enExample) |
| LT (1) | LT2818478T (enExample) |
| MX (1) | MX358390B (enExample) |
| MY (2) | MY186903A (enExample) |
| PL (2) | PL2663575T3 (enExample) |
| PT (2) | PT2663575E (enExample) |
| RS (2) | RS53683B1 (enExample) |
| RU (2) | RU2634417C2 (enExample) |
| SG (3) | SG10202100485XA (enExample) |
| SI (2) | SI2818478T1 (enExample) |
| SM (2) | SMT201700222T1 (enExample) |
| WO (1) | WO2013063556A1 (enExample) |
| ZA (1) | ZA201402635B (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3010323T3 (en) | 2009-10-06 | 2025-04-02 | Regeneron Pharma | Genetically modified mice and engraftment |
| KR102714361B1 (ko) | 2011-02-15 | 2024-10-11 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 ｍ－ｃｓｆ 마우스 |
| PL2663575T3 (pl) | 2011-10-28 | 2015-03-31 | Regeneron Pharma | Humanizowane IL-6 i receptor IL-6 |
| US20130261016A1 (en) * | 2012-03-28 | 2013-10-03 | Meso Scale Technologies, Llc | Diagnostic methods for inflammatory disorders |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| KR102473555B1 (ko) | 2012-09-07 | 2022-12-05 | 예일 유니버시티 | 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 |
| WO2014042251A1 (ja) * | 2012-09-13 | 2014-03-20 | 中外製薬株式会社 | 遺伝子ノックイン非ヒト動物 |
| IL311744B2 (en) * | 2012-11-05 | 2025-10-01 | Regeneron Pharma | Genetically modified non-human animals and methods of using them |
| LT2958938T (lt) | 2013-02-20 | 2019-07-25 | Regeneron Pharmaceuticals, Inc. | Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius |
| EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| GB2513884B (en) | 2013-05-08 | 2015-06-17 | Univ Bristol | Method and apparatus for producing an acoustic field |
| PT4269430T (pt) * | 2013-09-23 | 2025-08-06 | Regeneron Pharma | Animais não-humanos com um gene humanizado de proteína reguladora de sinal |
| EP3138397B1 (en) * | 2013-10-15 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized il-15 animals |
| MX356809B (es) | 2013-11-19 | 2018-06-13 | Regeneron Pharma | Animales no humanos que tienen un gen del factor activador de celulas b. |
| EP3071025B1 (en) * | 2013-11-19 | 2018-10-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| US9612658B2 (en) | 2014-01-07 | 2017-04-04 | Ultrahaptics Ip Ltd | Method and apparatus for providing tactile sensations |
| CA2934965A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| RU2700484C2 (ru) | 2014-04-08 | 2019-09-17 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| NO2785538T3 (enExample) * | 2014-05-07 | 2018-08-04 | ||
| KR20250096864A (ko) | 2014-05-19 | 2025-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
| US9497945B2 (en) | 2014-05-30 | 2016-11-22 | Regeneron Pharmaceuticals, Inc. | Humanized dipeptidyl peptidase IV (DPP4) animals |
| CN106604635B (zh) * | 2014-06-19 | 2020-01-14 | 瑞泽恩制药公司 | 具有人源化程序性细胞死亡1基因的非人动物 |
| GB2530036A (en) | 2014-09-09 | 2016-03-16 | Ultrahaptics Ltd | Method and apparatus for modulating haptic feedback |
| DK3223605T3 (da) | 2014-11-24 | 2020-11-16 | Regeneron Pharma | Ikke-humane dyr, der eksprimerer humaniseret cd3-kompleks |
| EP3086637B1 (en) * | 2014-12-05 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 47 gene |
| MX2017007636A (es) | 2014-12-09 | 2018-03-28 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado. |
| KR102515997B1 (ko) | 2015-02-20 | 2023-03-29 | 울트라햅틱스 아이피 엘티디 | 햅틱 시스템에서의 인식 |
| ES2908299T3 (es) | 2015-02-20 | 2022-04-28 | Ultrahaptics Ip Ltd | Mejoras del algoritmo en un sistema háptico |
| KR20240132525A (ko) | 2015-04-06 | 2024-09-03 | 리제너론 파아마슈티컬스, 인크. | 비인간 동물에서의 인간화 t 세포 매개 면역반응 |
| CN107896479B (zh) | 2015-04-13 | 2021-07-13 | 再生元制药公司 | 人源化SIRPα-IL15敲入小鼠及其使用方法 |
| US10818162B2 (en) | 2015-07-16 | 2020-10-27 | Ultrahaptics Ip Ltd | Calibration techniques in haptic systems |
| AU2016358101B2 (en) | 2015-11-20 | 2022-12-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized Lymphocyte-activation gene 3 |
| KR102851747B1 (ko) | 2015-12-08 | 2025-08-28 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화 조성물 및 방법 |
| US11189140B2 (en) | 2016-01-05 | 2021-11-30 | Ultrahaptics Ip Ltd | Calibration and detection techniques in haptic systems |
| KR102487839B1 (ko) | 2016-02-04 | 2023-01-12 | 리제너론 파마슈티칼스 인코포레이티드 | 조작된 angptl8 유전자를 갖는 비인간 동물 |
| SG10202001578RA (en) | 2016-02-29 | 2020-04-29 | Regeneron Pharma | Rodents having a humanized tmprss gene |
| CN109640644B (zh) | 2016-06-03 | 2021-10-26 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| US10531212B2 (en) | 2016-06-17 | 2020-01-07 | Ultrahaptics Ip Ltd. | Acoustic transducers in haptic systems |
| US10268275B2 (en) | 2016-08-03 | 2019-04-23 | Ultrahaptics Ip Ltd | Three-dimensional perceptions in haptic systems |
| US10755538B2 (en) | 2016-08-09 | 2020-08-25 | Ultrahaptics ilP LTD | Metamaterials and acoustic lenses in haptic systems |
| CN107815467B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| US10943578B2 (en) | 2016-12-13 | 2021-03-09 | Ultrahaptics Ip Ltd | Driving techniques for phased-array systems |
| US10497358B2 (en) | 2016-12-23 | 2019-12-03 | Ultrahaptics Ip Ltd | Transducer driver |
| CN108467873B (zh) | 2017-03-17 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
| WO2018177441A1 (en) | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
| CN108588126B (zh) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
| EP3585162B1 (en) | 2017-09-29 | 2023-08-30 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| US11531395B2 (en) | 2017-11-26 | 2022-12-20 | Ultrahaptics Ip Ltd | Haptic effects from focused acoustic fields |
| CA3076377A1 (en) | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized trkb locus |
| WO2019122912A1 (en) | 2017-12-22 | 2019-06-27 | Ultrahaptics Limited | Tracking in haptic systems |
| EP3729418B1 (en) | 2017-12-22 | 2024-11-20 | Ultrahaptics Ip Ltd | Minimizing unwanted responses in haptic systems |
| CA3093850A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| WO2019211616A1 (en) | 2018-05-02 | 2019-11-07 | Ultrahaptics Limited | Blocking plate structure for improved acoustic transmission efficiency |
| SMT202400300T1 (it) * | 2018-07-16 | 2024-09-16 | Regeneron Pharma | Modelli di roditori della sindrome ditra e loro utilizzo |
| US11098951B2 (en) | 2018-09-09 | 2021-08-24 | Ultrahaptics Ip Ltd | Ultrasonic-assisted liquid manipulation |
| US11378997B2 (en) | 2018-10-12 | 2022-07-05 | Ultrahaptics Ip Ltd | Variable phase and frequency pulse-width modulation technique |
| WO2020125639A1 (en) * | 2018-12-17 | 2020-06-25 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| US12373033B2 (en) | 2019-01-04 | 2025-07-29 | Ultrahaptics Ip Ltd | Mid-air haptic textures |
| WO2020141330A2 (en) | 2019-01-04 | 2020-07-09 | Ultrahaptics Ip Ltd | Mid-air haptic textures |
| CN111218425B (zh) * | 2019-01-17 | 2022-02-08 | 百奥赛图(北京)医药科技股份有限公司 | 人源化转基因动物 |
| CN117178959A (zh) | 2019-04-04 | 2023-12-08 | 瑞泽恩制药公司 | 包括人源化凝血因子12基因座的非人动物 |
| US11842517B2 (en) | 2019-04-12 | 2023-12-12 | Ultrahaptics Ip Ltd | Using iterative 3D-model fitting for domain adaptation of a hand-pose-estimation neural network |
| US20220340926A1 (en) * | 2019-05-27 | 2022-10-27 | Transgenic Inc. | Exon-humanized mouse |
| AU2020286382A1 (en) | 2019-06-04 | 2021-11-04 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| MX2021015122A (es) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Animales no humanos que comprenden un locus de albumina humanizado. |
| US11374586B2 (en) | 2019-10-13 | 2022-06-28 | Ultraleap Limited | Reducing harmonic distortion by dithering |
| CA3154040A1 (en) | 2019-10-13 | 2021-04-22 | Benjamin John Oliver LONG | Dynamic capping with virtual microphones |
| WO2021090028A1 (en) | 2019-11-08 | 2021-05-14 | Ultraleap Limited | Tracking techniques in haptics systems |
| CN111304246B (zh) * | 2019-12-17 | 2021-05-04 | 百奥赛图江苏基因生物技术有限公司 | 一种人源化细胞因子动物模型、制备方法及应用 |
| US11715453B2 (en) | 2019-12-25 | 2023-08-01 | Ultraleap Limited | Acoustic transducer structures |
| WO2021154791A1 (en) * | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| AU2021261267A1 (en) | 2020-04-21 | 2022-09-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized Cxcl13 gene |
| US11816267B2 (en) | 2020-06-23 | 2023-11-14 | Ultraleap Limited | Features of airborne ultrasonic fields |
| US11886639B2 (en) | 2020-09-17 | 2024-01-30 | Ultraleap Limited | Ultrahapticons |
| CN118511853A (zh) | 2021-03-31 | 2024-08-20 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| US20240224964A9 (en) | 2022-09-29 | 2024-07-11 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0786007A1 (en) * | 1994-10-14 | 1997-07-30 | Basf Aktiengesellschaft | Transgenic nonhuman animal having functionally disrupted interleukin-1-beta converting enzyme gene |
| EP1884524A3 (en) | 1994-10-21 | 2008-06-25 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment of diseases caused by IL-6 production |
| US20030082721A1 (en) * | 2001-01-17 | 2003-05-01 | Tai-Jay Chang | Transgenic animals expressing androgen receptor complex-associated protein |
| CN1560081A (zh) * | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用 |
| PL2767161T3 (pl) | 2004-10-19 | 2018-09-28 | Regeneron Pharmaceuticals, Inc. | Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej |
| GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| CA2661848C (en) * | 2006-09-01 | 2015-02-03 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| FR2942218A1 (fr) | 2009-02-13 | 2010-08-20 | Eurocave Sa | Appareil de service au verre d'un liquide, notamment de vin |
| ES3010323T3 (en) * | 2009-10-06 | 2025-04-02 | Regeneron Pharma | Genetically modified mice and engraftment |
| JP5595517B2 (ja) * | 2009-12-21 | 2014-09-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ＦｃγＲマウス |
| KR102714361B1 (ko) | 2011-02-15 | 2024-10-11 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 ｍ－ｃｓｆ 마우스 |
| TWI681970B (zh) | 2011-09-30 | 2020-01-11 | 日商中外製藥股份有限公司 | 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子 |
| DK2770821T3 (da) | 2011-10-28 | 2017-11-27 | Regeneron Pharma | Genetisk modificerede major histocompatibility-kompleks-mus |
| PL2663575T3 (pl) | 2011-10-28 | 2015-03-31 | Regeneron Pharma | Humanizowane IL-6 i receptor IL-6 |
| KR101926442B1 (ko) | 2011-10-28 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | 키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스 |
-
2012
- 2012-10-29 PL PL12795905T patent/PL2663575T3/pl unknown
- 2012-10-29 RS RS20140677A patent/RS53683B1/sr unknown
- 2012-10-29 RS RS20170430A patent/RS55949B1/sr unknown
- 2012-10-29 ES ES12795905.4T patent/ES2525368T3/es active Active
- 2012-10-29 WO PCT/US2012/062379 patent/WO2013063556A1/en not_active Ceased
- 2012-10-29 SG SG10202100485XA patent/SG10202100485XA/en unknown
- 2012-10-29 CN CN201810620759.8A patent/CN108866101A/zh active Pending
- 2012-10-29 SI SI201230941A patent/SI2818478T1/sl unknown
- 2012-10-29 PT PT127959054T patent/PT2663575E/pt unknown
- 2012-10-29 MX MX2014004900A patent/MX358390B/es active IP Right Grant
- 2012-10-29 ES ES14177863.9T patent/ES2624605T3/es active Active
- 2012-10-29 RU RU2014121324A patent/RU2634417C2/ru active
- 2012-10-29 EP EP12795905.4A patent/EP2663575B1/en active Active
- 2012-10-29 SG SG11201400945UA patent/SG11201400945UA/en unknown
- 2012-10-29 DK DK12795905.4T patent/DK2663575T3/en active
- 2012-10-29 HU HUE14177863A patent/HUE033400T2/en unknown
- 2012-10-29 BR BR112014008529A patent/BR112014008529A2/pt not_active Application Discontinuation
- 2012-10-29 PT PT141778639T patent/PT2818478T/pt unknown
- 2012-10-29 RU RU2017129763A patent/RU2751240C2/ru active
- 2012-10-29 KR KR1020147014316A patent/KR102084927B1/ko active Active
- 2012-10-29 MY MYPI2017703646A patent/MY186903A/en unknown
- 2012-10-29 SM SM20170222T patent/SMT201700222T1/it unknown
- 2012-10-29 IN IN3920CHN2014 patent/IN2014CN03920A/en unknown
- 2012-10-29 KR KR1020207005686A patent/KR102234632B1/ko active Active
- 2012-10-29 CA CA2853731A patent/CA2853731C/en active Active
- 2012-10-29 DK DK14177863.9T patent/DK2818478T3/en active
- 2012-10-29 LT LTEP14177863.9T patent/LT2818478T/lt unknown
- 2012-10-29 CN CN201280065013.6A patent/CN104039821A/zh active Pending
- 2012-10-29 JP JP2014539105A patent/JP6120451B2/ja active Active
- 2012-10-29 US US13/662,880 patent/US8878001B2/en active Active
- 2012-10-29 SI SI201230111T patent/SI2663575T1/sl unknown
- 2012-10-29 SG SG10201600965YA patent/SG10201600965YA/en unknown
- 2012-10-29 HR HRP20141192AT patent/HRP20141192T1/hr unknown
- 2012-10-29 MY MYPI2014000768A patent/MY172726A/en unknown
- 2012-10-29 PL PL14177863T patent/PL2818478T3/pl unknown
- 2012-10-29 EP EP14177863.9A patent/EP2818478B1/en active Active
-
2014
- 2014-04-03 IL IL231896A patent/IL231896B/en active IP Right Grant
- 2014-04-10 ZA ZA2014/02635A patent/ZA201402635B/en unknown
- 2014-09-19 US US14/490,875 patent/US9125386B2/en active Active
- 2014-09-19 US US14/490,877 patent/US9078418B2/en active Active
- 2014-12-11 CY CY20141101035T patent/CY1116614T1/el unknown
- 2014-12-15 SM SM201400187T patent/SMT201400187B/xx unknown
-
2015
- 2015-06-10 US US14/735,710 patent/US9392777B2/en active Active
- 2015-07-30 AU AU2015207889A patent/AU2015207889B2/en active Active
-
2016
- 2016-01-18 IL IL243665A patent/IL243665B/en active IP Right Grant
- 2016-01-18 IL IL243666A patent/IL243666B/en active IP Right Grant
- 2016-06-09 US US15/177,582 patent/US9622460B2/en active Active
- 2016-11-14 US US15/350,739 patent/US10004211B2/en active Active
- 2016-11-18 JP JP2016224713A patent/JP2017035115A/ja active Pending
-
2017
- 2017-04-28 HR HRP20170656TT patent/HRP20170656T1/hr unknown
- 2017-04-28 CY CY20171100474T patent/CY1118952T1/el unknown
-
2018
- 2018-06-06 US US16/001,074 patent/US10433528B2/en active Active
-
2019
- 2019-01-28 IL IL264508A patent/IL264508B/en active IP Right Grant
- 2019-07-03 US US16/502,197 patent/US11102962B2/en active Active
-
2021
- 2021-07-26 US US17/385,039 patent/US12239111B2/en active Active
-
2025
- 2025-01-29 US US19/039,847 patent/US20250287931A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
Non-Patent Citations (4)
| Title |
|---|
| American j. Pathology vol.157 no.5 pp.1485-1493(2000.11.30) |
| J. Exper. Med. vol.185 no.4 pp.755-766(1997.02.17) |
| Proc. Natl. Acad. Sci. USA vol.86 no.19 pp.7547-7551(1989.10.31) |
| Proc. Natl. Acad. Sci. USA vol.92 pp.4862-4866(1995.05.31) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12239111B2 (en) | Humanized IL-6 and IL-6 receptor | |
| AU2012327206B2 (en) | Humanized IL-6 and IL-6 receptor | |
| HK1205135B (en) | Humanized il-6 and il-6 receptor | |
| HK1190408B (en) | Humanized il-6 and il-6 receptor | |
| NZ623145B2 (en) | Humanized il-6 and il-6 receptor | |
| NZ709432B2 (en) | Humanized il-6 and il-6 receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140527 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20171025 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190430 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20191128 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20200226 |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200228 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200302 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20230126 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240215 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250210 Start annual number: 6 End annual number: 6 |